Use of IsoPSA to guide long-term management

Panelists discuss how IsoPSA’s predictive performance over extended time frames contributes to long-term management strategies for patients at risk of prostate cancer. They emphasize that the ability to identify low-risk patients with sustained negative results allows clinicians to safely defer invasive procedures while still maintaining vigilance.

Panelists discuss how long-term predictive value sets IsoPSA apart from other biomarkers, which may provide only a snapshot of risk at one point in time. The consistency of risk prediction across years allows for better continuity of care, more effective surveillance, and improved patient confidence in management decisions.

Panelists discuss how these features help guide personalized follow-up strategies, reducing unnecessary interventions while ensuring timely care for patients at higher risk. In comparison with other diagnostic tools, IsoPSA’s durability as a predictor makes it a strong candidate for integration into clinical algorithms.